[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin, 2018; 68, 394−424. doi: 10.3322/caac.21492 |
[2] |
Zhang M, Tuo JY, Li GC, et al. Cancer incidence and mortality in Hubei cancer registries, 2013. Cancer Res Prev Treat, 2018; 45, 414−9. (In Chinese |
[3] |
Harrison C. Cancer: IL-22: linking inflammation and cancer. Nat Rev Drug Discov, 2013; 12, 504. doi: 10.1038/nrd4058 |
[4] |
Wolk K, Witte E, Witte K, et al. Biology of interleukin-22. Semin Immunopathol, 2010; 32, 17−31. doi: 10.1007/s00281-009-0188-x |
[5] |
Wang JD, Li CD, Wan FT, et al. The rs1550117 A>G variant in DNMT3A gene promoter significantly increases non-small cell lung cancer susceptibility in a Han Chinese population. Oncotarget, 2017; 8, 23470−8. doi: 10.18632/oncotarget.15625 |
[6] |
Jiang RQ, Tan ZM, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology, 2011; 54, 900−9. doi: 10.1002/hep.24486 |
[7] |
Zhang WC, Chen YY, Wei HM, et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res, 2008; 14, 6432−9. doi: 10.1158/1078-0432.CCR-07-4401 |
[8] |
Liu T, Peng LS, Yu PW, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol, 2012; 32, 1332−9. doi: 10.1007/s10875-012-9718-8 |
[9] |
Welter JF, Gali H, Crish JF, et al. Regulation of human involucrin promoter activity by POU domain proteins. J Biol Chem, 1996; 271, 14727−33. doi: 10.1074/jbc.271.25.14727 |